Results 231 to 240 of about 510,697 (405)

Patch Testing Under Biologics: Six Cases From a Tertiary Centre

Contact Dermatitis, EarlyView.
Alessandra Chiei‐Gallo, Francesca Barei, Angelo V. Marzano, Silvia M. Ferrucci   +3 more
wiley   +1 more source

Efficacy and safety of brodalumab in palmoplantar pustulosis: A 68‐week randomized Phase 3 trial

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This open‐label study is a continuation of the 16‐week double‐blind, Phase 3 trial assessing the efficacy and safety of brodalumab 210 mg subcutaneously, till a 68‐week extension period. Continued improvement was seen in the PPPASI 50/75/90 responses, PPPSI scores, PGA 0/1 responses and DLQI. Abstract Background The efficacy and safety of brodalumab in
Masamoto Murakami, Yukari Okubo, Satomi Kobayashi, Natsuko Kikuta, Yoshiumi Ouchi, Kenta Shishido, Tadashi Terui   +6 more
wiley   +1 more source

Incidence rate and risk factors of arrhythmias in patients with psoriatic arthritis. [PDF]

RMD Open
Almansouri AY, Li J, Bumbulis L, Alhadari A, Colaco K, Harvey P, Akhtari S, Chandran V, Gladman DD, Cook RJ, Eder L.   +10 more
europepmc   +1 more source

Successful Screening of Undiagnosed Psoriatic Arthritis in Primary Care Utilising Digital Interventions Within a Quality Improvement Programme [PDF]

Antoni Chan, Matthew Pearce, Liz Van Rossen   +2 more
openalex   +1 more source

Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In this Phase 3 trial of Japanese patients with moderate to severe PPP (NCT05174065), significantly more patients achieved PPPASI‐50 at Week 16 with apremilast versus placebo. Patient‐reported outcomes, including pruritus and pain/discomfort, also showed significantly greater decreases at Week 16 with apremilast versus placebo.
Tadashi Terui, Yukari Okubo, Satomi Kobayashi, Akimichi Morita, Shinichi Imafuku, Yayoi Tada, Masatoshi Abe, Bruce Strober, Melinda Gooderham, Wendy Zhang, Junichiro Shimauchi, Masafumi Yaguchi, Takeshi Kimura, Ryuichi Ogawa, Hamid Amouzadeh, Masamoto Murakami   +15 more
wiley   +1 more source

Effectiveness of Tofacitinib in Patients with Psoriatic Arthritis Initiating Monotherapy Versus Combination Therapy: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. [PDF]

Rheumatol Ther
Ogdie A, Middaugh N, Blachley T, Bourgeois T, Ling YL, Mundayat R, Fallon L, Masri KR, Mease PJ.   +8 more
europepmc   +1 more source

Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis [PDF]

, 2005
Baeten, Dominique, BOOTS, AM, CANETE, JD, De Keyser, Filip, De Rycke, Leen, FOELL, D, Kruithof, Elli, ROTH, J, VANDOOREN, BERNARD, Veys, Eric   +9 more
core  

Pathophysiology of Atherosclerosis in Psoriatic Arthritis: New Insights into Inflammation and Lipid Metabolism [PDF]

Marius Semionov, Eugeniu Russu
openalex   +1 more source

Impact of weight‐loss interventions on psoriasis severity: A systematic review and meta‐analysis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Weight‐loss interventions were associated with clinically and statistically significant improvements in psoriasis severity (PASI and PASI 75) and quality of life (DLQI). These findings support the role of weight‐loss interventions as effective adjuncts to medical therapy and their integration into holistic psoriasis care.
Sarah Morrow, Poppy Hawkins, Christopher E. M. Griffiths, Thanasis G. Tektonidis, Eli Harriss, Jadine Scragg, Susan Jebb   +6 more
wiley   +1 more source

Effect of Nutritional Ingredients on Disease Activation in Psoriatic Arthritis. [PDF]

Arch Rheumatol
Varkal G, Akarca NN, Türk İ, Yetişir A, Mete B.   +4 more
europepmc   +1 more source